Acrivon Therapeutics, Inc. (ACRV)

Acrivon Therapeutics' stock price has experienced significant volatility and a general decline over the past year. In March 2026, the company reported its Fourth Quarter and Full Year 2025 financial results, highlighting a confirmed overall response rate of 52% in serous endometrial cancer from its Phase 2b ACR-368 study, leading to a stock gain and positive analyst ratings. In February 2026, the company presented at the TD Cowen 46th Annual Health Care Conference and held an Endometrial Cancer KOL Panel. In January 2026, clinical data updates for ACR-368 and ACR-2316 were released, showing a 39% response rate in endometrial cancer, causing a pre-market stock surge, but a preliminary earnings report resulted in a price decrease. In November 2025, HC Wainwright & Co. issued a "Buy" rating, and in August 2025, Oppenheimer issued an "Outperform" rating. The stock's weekly volatility has been stable but remains higher than 75% of US stocks, with a price of $1.40 as of March 31, 2026.

There is no information available regarding demand seasonality for Acrivon Therapeutics, Inc.'s products and services. As a clinical-stage biopharmaceutical company, its revenue generation primarily comes from licensing agreements, collaborative research, and grants, rather than direct product sales to consumers. The demand for its drug candidates is driven by the progression of clinical trials and regulatory approvals, rather than seasonal consumer patterns.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision oncology medicines, utilizing its proprietary Generative Phosphoproteomics AP3 platform to design drug candidates and match them to patients. The company's lead clinical candidate, ACR-368, is in a potentially registrational Phase 2 trial across multiple solid tumor types and has received FDA Fast Track and Breakthrough Device designations. ACR-2316, a dual WEE1 and PKMYT1 inhibitor, is advancing in Phase 1 clinical trials, and ACR-6840 targets CDK11. Additionally, the company has a preclinical cell cycle program based on the AP3 platform.

Acrivon Therapeutics, Inc. operates globally with its team based out of Greater Boston in the United States and Medicon Valley in Southern Scandinavia. The company's headquarters are located in Watertown, Massachusetts, United States.

Information specifically detailing Acrivon Therapeutics, Inc.'s brand reputation is not readily available. The available information focuses on clinical trial progress, financial results, and stock performance.

Acrivon Therapeutics, Inc. has a mixed ownership structure comprising institutional shareholders, insiders, and retail investors. Institutional investors hold approximately 34.96% to 49.07% of the stock, insiders own around 38.25% to 44.33%, and retail investors hold approximately 13.71% to 15.77%. Major institutional owners include Ra Capital Management, L.p., Sands Capital Ventures, LLC, and Citadel Advisors Llc. Key individual owners and insiders include Chione Ltd, Kristina Masson, and Peter Blume-Jensen, with Peter Kolchinsky owning the most shares among individuals.